Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38:1669–74. https://doi.org/10.1007/s00259-011-1835-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56. https://doi.org/10.1007/s00259-008-0778-1.

Article  CAS  PubMed  Google Scholar 

Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58. https://doi.org/10.2967/jnumed.110.075101.

Article  CAS  PubMed  Google Scholar 

Alsadik S, Gnanasegaran G, Chen L, Quigley AM, Mandair D, Toumpanakis C, et al. Single centre retrospective review of outcome of (177) Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors. J Neuroendocrinol. 2022;34: e13210. https://doi.org/10.1111/jne.13210.

Article  CAS  PubMed  Google Scholar 

Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42:1955–63. https://doi.org/10.1007/s00259-015-3105-7.

Article  CAS  PubMed  Google Scholar 

Virgolini I. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur J Nucl Med Mol Imaging. 2015;42:1949–54. https://doi.org/10.1007/s00259-015-3153-z.

Article  PubMed  Google Scholar 

Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9–15. https://doi.org/10.1007/s00259-002-0982-3.

Article  CAS  PubMed  Google Scholar 

Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss A, Gruber L, et al. Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning - A retrospective analysis. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41:138–45. https://doi.org/10.1016/j.remnie.2021.04.007.

Article  PubMed  Google Scholar 

Zandee WT, Brabander T, Blažević A, Kam BLR, Teunissen JJM, Feelders RA, et al. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. 2019;104:1336–44. https://doi.org/10.1210/jc.2018-01991.

Article  PubMed  Google Scholar 

Zandee WT, Feelders RA, Smit Duijzentkunst DA, Hofland J, Metselaar RM, Oldenburg RA, et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 2019;181:45–53. https://doi.org/10.1530/eje-18-0901.

Article  CAS  PubMed  Google Scholar 

Sitani K, Parghane R, Talole S, Basu S. The efficacy, toxicity and survival of salvage retreatment PRRT with (177)Lu-DOTATATE in patients with progressive NET following initial course of PRRT. Br J Radiol. 2022;95:20210896. https://doi.org/10.1259/bjr.20210896.

Article  PubMed  Google Scholar 

Rudisile S, Gosewisch A, Wenter V, Unterrainer M, Böning G, Gildehaus FJ, et al. Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019;19:788. https://doi.org/10.1186/s12885-019-6000-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519–36. https://doi.org/10.1007/978-3-642-27994-2_30.

Article  CAS  PubMed  Google Scholar 

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406–16. https://doi.org/10.1089/cbr.2006.325.

Article  CAS  PubMed  Google Scholar 

Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics. 2012;2:437–47. https://doi.org/10.7150/thno.3645.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, et al. Safety of multiple repeated cycles of (177)Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44:1207–14. https://doi.org/10.1007/s00259-017-3652-1.

Article  CAS  PubMed  Google Scholar 

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23:4617–24. https://doi.org/10.1158/1078-0432.Ccr-16-2743.

Article  CAS  PubMed  Google Scholar 

Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, et al. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases. Int J Endocrinol. 2019;2019:9871319. https://doi.org/10.1155/2019/9871319.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21:1794–803. https://doi.org/10.1093/annonc/mdq022.

Article  CAS  PubMed  Google Scholar 

Menda Y, Madsen MT, O’Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, et al. (90)Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med. 2018;59:1692–8. https://doi.org/10.2967/jnumed.117.202903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. https://doi.org/10.1007/s00259-014-2893-5.

Article  CAS  PubMed  Google Scholar 

Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41:223–30. https://doi.org/10.1007/s00259-013-2578-5.

Article  CAS  PubMed  Google Scholar 

Kunikowska J, Pawlak D, Bak MI, Kos-Kudla B, Mikolajczak R, Krolicki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with (90)Y/(177)Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017;31:347–56. https://doi.org/10.1007/s12149-017-1163-6.

Article  CAS  PubMed  Google Scholar 

Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97. https://doi.org/10.1007/s00259-011-1833-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferdinandus J, Fendler WP, Lueckerath K, Berliner C, Kurzidem S, Hadaschik E, et al. Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. J Nucl Med. 2022;63:396–8. https://doi.org/10.2967/jnumed.121.262344.

Article  PubMed  Google Scholar 

Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med. 2019;44:e329–35. https://doi.org/10.1097/rlu.0000000000002532.

Article  PubMed  Google Scholar 

Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne). 2022;9:1034315. https://doi.org/10.3389/fmed.2022.1034315.

Article  PubMed  Google Scholar 

Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE. J Nucl Med. 2021;62:386–92. https://doi.org/10.2967/jnumed.120.248658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:947–57. https://doi.org/10.1007/s00259-019-04530-1.

Article  CAS  PubMed  Google Scholar 

Jiang Y, Liu Q, Wang G, Zhang J, Zhu Z, Chen X. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Clin Nucl Med. 2023;48:e289–93. https://doi.org/10.1097/RLU.0000000000004642.

Article  PubMed  Google Scholar